Viekira Pak FDA Approval History
FDA Approved: Yes (First approved December 19, 2014)
Brand name: Viekira Pak
Generic name: ombitasvir/paritaprevir/ritonavir with dasabuvir
Dosage form: Tablets
Company: AbbVie Inc.
Treatment for: Hepatitis C
Viekira Pak (ombitasvir/paritaprevir/ritonavir with dasabuvir) is an NS5A inhibitor, NS3/4A protease inhibitor and CYP3A inhibitor combination co-packaged with a non-nucleoside NS5B palm polymerase inhibitor for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection.
Development Timeline for Viekira Pak
|Dec 19, 2014||FDA Approves Viekira Pak (ombitasvir/paritaprevir/ritonavir with dasabuvir) to Treat Hepatitis C|
|Apr 22, 2014||AbbVie Submits NDA to FDA for Oral, Interferon-Free Therapy for the Treatment of Hepatitis C|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.